Outlook Therapeutics Inc - Warrants - Series A (18/02/2022)
OTLKW - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.1M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.10 Million |
|---|---|
| Enterprise Value | $-7,139,700.00 |
| Earnings per Share | $-1.79 |
| Beta | 0 |
| Outstanding Shares | 136,743,333 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | -67771217.78% |
| Return on Invested Capital | 1256681106.34% |
Valuation & Multiples
| P/E Ratio | -0.43 |
|---|---|
| PEG | 0.43 |
| Price to Sales | 0.0 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | - |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Outlook Therapeutics Inc
8 employees
CEO: Lawrence Kenyon
